Doxil/Caelyx (Ovarian Cancer) ' Analysis and Forecasts to 2020

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Doxil/Caelyx (Ovarian Cancer) ' Analysis and Forecasts to 2020
Published on October 2011

Report Summary


Summary

GlobalData's pharmaceuticals report, 'Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020' provides Doxil/Caelyx sales
estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales,
competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes
information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData's proprietary
databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured
press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's
team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU and Japan (seven major markets)
- Analysis and review of Doxil/Caelyx including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Doxil/Caelyx including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales estimates for 2002-2020 for Doxil/Caelyx in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4

Doxil/Caelyx (Ovarian Cancer) ' Analysis and Forecasts to 2020 (From Slideshare) Page 1/5


2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 7
3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11
4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 12
5 Doxil 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Study 15
5.4 Approval History of Doxil 15
5.5 Factors Affecting Sales of Doxil 16
5.5.1 Orphan Drug Exclusivity 16
5.5.2 Patent Expiry in Europe 16
5.5.3 Strong Pipeline 16
5.6 Drug Evaluation 17
5.6.1 Drug Risk Benefit Score 17
5.6.2 Intensity of Competition 17
5.7 Sales Forecast 18
5.7.1 Target Patient Pool of Doxil 18
5.7.2 Dosing 18
5.7.3 Market Penetration 19
5.7.4 Annual Cost of Therapy 19
5.7.5 Sales Projections of Doxil 20
6 Ovarian Cancer Market: Appendix 29
6.1 Market Definitions 29
6.2 List of Abberiviations 29
6.3 Research Methodology 29
6.3.1 Coverage 29
6.3.2 Secondary Research 29
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 31



6.3.6 Net Annual Dosing 31
6.3.7 Annual Cost of Therapy 31
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 32
6.5 Disclaimer 32
6.6 Sources 33

1.1 List of Tables

Table 1: Ovarian Cancer, Incidences and Mortality, 2008'2030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 2009'2020 8
Table 3: Detailed TNM Classification 13
Table 4: Study Details 15
Table 5: Approval and Expiry of Doxil 15
Table 6: Drug Risk Benefit Score 17
Table 7: Doxil, Ovarian Cancer, Global, Annual Cost of Therapy ($), 2011 19
Table 8: Doxil, Ovarian Cancer, Global, Sales Estimates ($m), 2002-2020 20
Table 9: Doxil, Ovarian Cancer, The US, Sales Estimates ($m), 2002-2020 21
Table 10: Doxil , Ovarian Cancer, The UK, Sales Estimates ($m), 2002-2015 22
Table 11: Doxil , Ovarian Cancer, France, Sales Estimates ($m), 2002-2015 23
Table 12: Doxil , Ovarian Cancer, Germany, Sales Estimates ($m), 2002-2015 24
Table 13: Doxil , Ovarian Cancer, Italy, Sales Estimates ($m), 2002-2015 25
Table 14: Doxil , Ovarian Cancer, Spain, Sales Estimates ($m), 2002-2015 26
Table 15: Doxil , Ovarian Cancer, Japan, Sales Estimates ($m), 2009-2020 27

1.2 List of Figures

Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 2009'2020 8
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 9
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 10
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 10
Figure 6: Broad Classification of Ovarian Cancer 12
Figure 7: Classification of Ovarian Cancer 14
Figure 8: Drug Model Diagram of Doxil 18
Figure 9: Doxil, Ovarian Cancer, Global, Sales Estimates ($m), 2002-2020 20
Figure 10: Doxil , Ovarian Cancer, The US, Sales Estimates ($m), 2002-2020 21
Figure 11: Doxil , Ovarian Cancer, The UK, Sales Estimates ($m), 2002-2015 22
Figure 12: Doxil , Ovarian Cancer, France, Sales Estimates ($m), 2002-2015 23
Figure 13: Doxil , Ovarian Cancer, Germany, Sales Estimates ($m), 2002-2015 24
Figure 14: Doxil , Ovarian Cancer, Italy, Sales Estimates ($m), 2002-2015 25
Figure 15: Doxil , Ovarian Cancer, Spain, Sales Estimates ($m), 2002-2015 26
Figure 16: Doxil , Ovarian Cancer, Japan, Sales Estimates ($m), 2009-2020 27
Figure 17: Doxil, Ovarian Cancer, Global, Sales Distribution (%), 2013 28
Figure 18: Drug Model Diagram 30
Figure 19: Patients Approved for the Drug 31


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Doxil/Caelyx (Ovarian Cancer) ' Analysis and Forecasts to 2020

Recommandé

Recommandé

Contenu connexe

En vedette

En vedette (19)

Plus de ReportLinker.com

Plus de ReportLinker.com (20)

Doxil/Caelyx (Ovarian Cancer) ' Analysis and Forecasts to 2020